24/7 Market News Snapshot 31 July, 2025 – Lantern Pharma Inc. Common Stock (NASDAQ:LTRN)

July 31, 2025

DENVER, Colo., 31 July, 2025 (www.247marketnews.com) – (NASDAQ:LTRN) are discussed in this article.
Lantern Pharma Inc. (LTRN) has experienced a notable surge in its stock price today, opening at $4.18 and currently trading at $4.476, representing a robust increase of roughly 11.62%. This upward movement follows a previous close of $4.01, indicating substantial momentum in the market. With a trading volume of 606.38K shares, the activity is notably above average, highlighting increased investor interest and potential for volatility. Technically, this rise suggests a bullish trend, contingent on sustaining above the key support level of $4.18. Market participants should closely monitor resistance at $4.50, as this may present breakout opportunities amid heightened trading conditions.

In parallel, Lantern Pharma has successfully concluded target enrollment for its Phase 2 HARMONIC™ clinical trial, bringing ten patients into the study ahead of schedule. This accomplishment has been facilitated through partnerships with five clinical sites, including an esteemed national cancer center. The trial is assessing the investigational drug LP-300 alongside established chemotherapy agents carboplatin and pemetrexed for never-smoker patients suffering from non-small cell lung cancer (NSCLC) who have experienced disease progression after prior treatment with tyrosine kinase inhibitors (TKIs).

Panna Sharma, President and CEO of Lantern Pharma, commented that completing Japanese enrollment ahead of schedule confirms the company’s international expansion strategy. This progress is crucial as the company approaches the generation of clinical data that may establish LP-300 as an effective treatment for never-smoker NSCLC patients, who currently lack approved options.

The global HARMONIC™ trial aims to include around 90 patients from various regions, focusing on the distinctive needs of never-smoker NSCLC. Initial results have shown an 86% clinical benefit rate among early U.S. patient cohorts, indicating a promising outlook. Lantern is actively pursuing collaboration opportunities to enhance the market potential of LP-300 and plans to share further clinical data updates later this quarter.

Related news for (LTRN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.